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Background: Peritoneal carcinomatosis is regarded as a common sign of advanced tumor stage, tumor progression or
local recurrence of appendiceal and colorectal cancer and is generally associated with poor prognosis. Although
survival of patients with advanced stage CRC has markedly improved over the last 20 years with systemic treatment,
comprising combination chemotherapy +/− monoclonal antibodies, the oncological outcome—especially of the
subgroup of patients with peritoneal metastases—is still unsatisfactory. In addition to systemic therapy, cytoreductive
surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are specific treatment options for a selected
group of these patients and may provide an additional therapeutic benefit in the framework of an interdisciplinary
treatment concept.
Methods/design: The COMBATAC trial is a prospective, multicenter, open-label, single-arm, single-stage phase II trial
investigating perioperative systemic polychemotherapy including cetuximab in combination with CRS and HIPEC
patients with histologically proven wild-type KRAS colorectal or appendiceal adenocarcinoma and synchronous or
metachronous peritoneal carcinomatosis. The planned total number of patients to be recruited is 60. The primary
endpoint is progression-free survival (PFS). Secondary endpoints include overall survival (OS), perioperative morbidity
and treatment-associated toxicity, feasibility of the combined treatment regimen, quality of life (QoL) and
histopathological regression after preoperative chemotherapy.
Discussion: The COMBATAC trial is designed to evaluate the feasibility and efficacy of the combined multidisciplinary
treatment regimen consisting of perioperative systemic combination chemotherapy plus cetuximab and CRS plus
bidirectional HIPEC with intraperitoneal oxaliplatin.
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Disease under study
Colorectal cancer (CRC) is the third most commonly diag-
nosed cancer in males and the second in female worldwide
and overall the fourth leading cause of cancer-related
death. Whereas the mortality associated with CRC slightly
decreased over the past 20 years the incidence is still in-
creasing in most countries [1,2]. More than 10% of patients
with CRC already show peritoneal carcinomatosis at the
time of initial diagnosis [3]. In about 25% of the cases there
is no evidence of further distant metastasis [4]. Moreover,
up to 25% of all patients with CRC develop peritoneal car-
cinomatosis during the natural course of their disease as a
common sign of tumor progression or recurrence. In con-
trast to lymphatic and hematologic spread of metastases,
intraperitoneal carcinomatosis develops by direct transco-
lonic tumor spread or tumor cell seeding during surgical
resection of the primary tumor [5-8]. Tumor cell distribu-
tion within the abdominal cavity results in avascular tumor
nodules that often cannot be efficiently addressed by sys-
temic chemotherapy [9]. Thus, peritoneal carcinomatosis
is mostly associated with poor prognosis. In the prospec-
tive European multicenter EVOCAPE 1 study, a median
survival of 5.2 months was reported out of the 118 patients
with peritoneal carcinomatosis arising from CRC during
the natural course of disease [10]. Another retrospective
analysis of 3,000 patients with peritoneal colon cancer dis-
semination reported a comparable median survival of
7 months [11].
First-line treatment of advanced colorectal cancer
Systemic chemotherapy for metastatic colorectal cancer
(mCRC) is mainly based on 5-FU with folinic acid (FA),
preferably given as 24–48 h infusion, or oral prodrugs
(e.g. capecitabine) in combination with either oxaliplatin
or irinotecan [12]. Several studies with different chemo
doublets could show median overall and progression-free
survival ranging from 15 to 23 and 7 to 14 months, re-
spectively, in patients with metastatic colorectal cancer
(Table 1). Recently, Falcone et al. has shown a triple chemo-
therapy regimen combining 5-FU/FA, oxaliplatin and irino-
tecan (FOLFOXIRI) to be superior to FOLFIRI as first-line
therapy [13]. In addition, triplets including targeted therapy
such as antibodies against the vascular endothelial growth
factor, VEGF (bevacizumab) or the epidermal growth factor
receptor EGFR (cetuximab or panitumab) have been proven
to be efficient in terms of prolonged overall and disease-
free survival in first line mCRC treatment [14]. Thus, PFS
reached up to 12 months and OS ranged from 17 to
30 months (Tables 1 and 2). Nevertheless, the efficacy of
the different triplet regimens may depend on tumor
biology-related factors (e.g. histology, dissemination pattern,
KRAS or BRAF mutation, anticipated chemosensitivity and
growth dynamics). However, triplets are recommended bythe recently published ESMO Consensus Guidelines for
first-line treatment or induction therapy for most of
patients with advanced colorectal cancer [12].
EGFR-targeted therapy for advanced colorectal cancer
The addition of targeted anticancer drugs against the epi-
dermal growth factor receptor (EGFR), the monoclonal
antibodies cetuximab and panitumumab, has further im-
proved patient outcome in advanced stage colorectal can-
cer (Tables 2). Two prospective trials showed a survival
benefit by adding cetuximab to best supportive care in
patients with chemotherapy-refractory mCRC leading to a
median OS of 6.4 and 6.1 months, respectively [38,39].
The BOND trial assigned patients with disease progression
within three months after irinotecan-based chemotherapy
to receive cetuximab with or without irinotecan. The me-
dian OS was 8.6 and 6.9 months, the time to progression
4.1 and 1.5 months, respectively [40]. In the randomized
phase III CRYSTAL study investigating first-line treatment
of mCRC the median PFS in the wild-type KRAS subgroup
was 9.9 months in the FOLFIRI/cetuximab arm versus
8.7 months in the FOLFIRI arm. Median OS was 24.9 and
21 months, respectively. In patients with mutant KRAS
status (n = 192) median PFS was reduced after additional
treatment with cetuximab (7.6 vs. 8.1 months) [33,41].
Similar observations are reported by Bokemeyer et al. after
subgroup analysis of the prospective randomized OPUS
study. The median progression-free survival rate was
7.2 months in both treatment arms with a 0.5 months
benefit for additional treatment with cetuximab in the
wild-type KRAS subgroup [34]. The results have been
confirmed by a recently published pooled analysis of the
CRYSTAL and OPUS trials [42].
Moreover, these observations are supported by the
PRIME study that showed a significant improvement of
PFS of untreated patients with wild-type KRAS mCRC by
adding the EGFR antibody panitumumab to FOLFOX-4.
Median PFS was 9.6 months in the panitumumab group
vs. 8.0 months in the control group. There was also a non-
significant benefit in overall survival (23.9 vs. 19.7 months)
[28]. Another prospective randomized phase III study
showed an increased PFS after adding panitumumab to
FOLFIRI in second-line treatment of patients with mCRC
(5.9 vs. 3.9 months) [43].
In contrast, the MRC COIN trial investigating the
addition of cetuximab to an oxaliplatin-based chemother-
apy for first-line treatment of patients with advanced CRC
could not reproduce these findings. Although the response
rate increased from 57% to 64% by adding cetuximab there
was no significant benefit in median OS (17.9 in the con-
trol group vs. 17.0 months in the cetuximab group) as well
as PFS (8.6 vs. 8.6 months). Nevertheless, in the subgroup
analysis the lack of benefit was only reported for oxalipla-
tin and fluoropyrimidine combinations plus cetuximab in
Table 1 Selected RCTs for systemic chemotherapy of advanced colorectal cancer
Author, year Pat. [n] Treatment regimen Median PFS [months] Median OS [months]
DeGramont, 2000 [15] 210 FOLFOX4 9.0 16.2
Giacchetti, 2000 [16] 100 FOLFOX 8.7 19.4
Douillard, 2000 [17] 199 FOLFIRI 6.7 17.4
Saltz, 2000 [18] 226 IFL 7.0 14.8
Tournigand, 2003 [19] 109 FOLFIRI/FOLFOX6 14.2 21.5
Hurwitz, 2004 [20] 402 IFL/bevacizumab 10.6 20.3
Goldberg, 2006 [21] 154 FOLFOX4 9.7 19.0
Falcone, 2007 [13] 122 FOLFOXIRI 9.8 22.6
Fuchs, 2008 [22,23] 57 FOLFIRI/bevacizumab 11.2 28.0
Saltz, 2008 [24] 699 FOLFOX4/bevacizumab 9.4 21.3
Hecht, 2009 [25] 823 FOLFOX/FOLFIRI/bev 11.4 24.5
+ panitumumab 10.0 19.4
Tebbutt, 2010 [26] 157 capecitabine/bevacizumab 8.5 -
Stathopoulos, 2010 [27] 114 IRI/5-FU/FA/bevacizumab - 22.0
108 IRI/5-FU/FA - 25.0
Douillard, 2010 [28] 1183 FOLFOX4/panitumumab 9.6 23.9
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recently published NORDIC-VII trial no benefit could be
shown for the addition of cetuximab to an oxaliplatin-
based combination with bolus 5-FU only (FLOX). In the
ITT analysis the median progression-free survival was
7.9 months in the control group vs. 8.3 months in the
cetuximab group, respectively [37].Systemic treatment of colorectal PM
Due to the fact that peritoneal metastases (PM) differ
from other metastatic sites regarding clinical course and
prognosis, Franko et al. published a pooled subgroup
analysis of 364 patients with mCRC from the two North
Central Cancer Treatment Group phase III trials N9741
and N9841. The patients were treated with oxaliplatin-
or irinotecan-based systemic chemotherapy. The 5-year
OS was 4.1% in patients with (additional) peritonealTable 2 Cetuximab for advanced colorectal cancer
Author, year Pat.
[n]
Treatment
regimen
Tabernero, 2007 [29] 43 FOLFOX/cetuximab
Borner, 2008 [30] 74 CAPOX/cetuximab
Arnold, 2008 [31] 49 FUFOX/cetuximab
Cartwright, 2008 [32] 70 CAPIRI/cetuximab
Van Cutsem, 2009 [33] 348* FOLFIRI/cetuximab
Bokemeyer, 2009 [34] 134* FOLFOX/cetuximab
Tol, 2009 [35] 755 CAPOX/bev/cet
Maughan, 2011 [36] 729* FOLFOX/CAPOX/cet
Tveit, 2012 [37] 566 FLOX/cetuximab
*wild-type KRAS.metastases (PM) vs. 6% in patients without PM, showing
a 30% relative reduction of OS in case of peritoneal carcin-
omatosis. Systemic chemotherapy with FOLFOX was su-
perior to irinotecan-based treatment regimens, irrespective
of the carcinomatosis status [44]. Klaver et al. analyzed the
survival of the subgroup of patients with PM at the time of
enrolment in the prospective clinical trials CAIRO and
CAIRO2. The median OS significantly decreased in the
PM group compared to patients without peritoneal tumor
spread (CAIRO: 10.4 vs. 17.3 months, CAIRO2: 15.2 vs.
20.7 months) [45]. In 63 patients with colorectal PM se-
lected from the French database that received several regi-
mens of modern systemic chemotherapy the median OS
was 23.9 months [46]. An Asian prospective single-arm
phase II study investigating FOLFOX-4 in patients with
peritoneal metastases from CRC reported a median time
to progression of 4.4 months and a median overall survival
of 21.5 months [47].Median PFS [months] Median OS [months]
+ cet - cet + cet - cet
12.3 - 30.5 -
7.2 5.8 20.5 16.5
8.1 - 28.2 -
8.1 - 20.5 -
9.9* 8.7* 24.9* 21*
7.7* 7.2* - -
9.4 10.7 19.4 20.3
8.6* 8.6* 17.0* 17.9*
8.3 7.9 19.7 20.4
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The combined treatment concept of cytoreductive surgery
(CRS) and hyperthermic intraperitoneal chemotherapy
(HIPEC) was introduced by Sugarbaker et al. in the early
1990’s and consists of complete macroscopic cytoreduc-
tion of all visible tumor nodules followed by local intraab-
dominal chemoperfusion at 41-42°C [48,49]. The aim of
HIPEC in patients with peritoneal carcinomatosis is to cir-
cumvent the peritoneal barrier and to obtain higher local
concentration of the cytostatic agents [50-52]. However,
until today the intraperitoneal or bidirectional chemother-
apeutic regimen is not standardized [53-56]. The addition
of hyperthermia may potentiate the effect of the cytostatic
agents by thermic cytotoxicity and induction of apoptosis.
Moreover, heating can improve tissue penetration of the
cytostatic agents [48,57,58].
Numerous retrospective analyses reported feasibility,
safety and efficacy of the combined treatment concept of
CRS and HIPEC in patients with peritoneal carcinoma-
tosis arising from CRC (Table 3). However, data from
prospective trials are still limited. Verwaal et al. reported
a prospective randomized phase III trial analyzing CRS
and HIPEC with MMC plus adjuvant chemotherapy with
5-FU/folinic acid compared to systemic chemotherapy
with 5-FU/folinic acid and palliative surgery, if possible.
After a median follow-up of 21.6 months, the experimen-
tal treatment arm showed a median overall survival of
22.3 months compared to 12.6 months in the standard
arm. In the subgroup of patients with complete macro-
scopic cytoreduction (CC-0/1) median survival was
42.9 months. Median progression-free survival was 12.6
and 7.7 months, respectively [59,60]. Another randomized
controlled trial was launched by a French group. This
study published by Elias et al. was designed to compare
CRS with early postoperative intraperitoneal chemothe-
rapy (EPIC) to CRS alone. After premature termination
due to recruitment difficulties a 2-year survival rate of 60%
was reported in 35 patients with complete macroscopic
cytoreduction [61]. In the comparative study published by
Mahteme et al. the median survival in the HIPEC group
was 32 months vs. 14 months in the control group. 5-year
survival rates were 28% and 5% respectively [62]. A multi-Table 3 CRS and HIPEC
Author, year Pat. [n] Cytostatic agents (HIPEC) Median
Pilati, 2003 [66] 34 MMC/DDP
Glehen, 2004 [67] 53 MMC
Glehen, 2004 [63] 506 MMC/LOHP
Shen, 2004 [68] 77 MMC
Verwaal, 03/08 [59,60] 105 MMC
Quenet, ASCO 08 [69] 37 LOHP/IRI
Elias, 2009 [46] 48 LOHP
Hompes, 2012 [65] 48 LOHPcenter registry study of 506 patients treated with CRS and
HIPEC for peritoneal carcinomatosis arising from colorec-
tal cancer reported median overall survival of 19.2 months.
In patients with complete macroscopic cytoreduction (CC-
0/1) the median survival was 32.4 months [63]. In numer-
ous observational studies the overall median survival ran-
ged from 15 to 32 months and from 28 to 60 months after
complete macroscopic cytoreduction (CC-0/1), respect-
ively [64]. Elias et al. compared 48 patients from the
French Multicenter Database with peritoneal carcinoma-
tosis arising from CRC who received palliative systemic
chemotherapy to 48 patients who underwent additional
CRS and bidirectional oxaliplatin-based HIPEC. The che-
motherapeutic regimen and the duration of systemic
chemotherapy were comparable in both groups. The me-
dian survival was 23.9 months in the control group vs.
62.7 months in the HIPEC group, and the 5-year survival
rate was 13% and 51%, respectively [46]. Comparable
results were obtained in a recently published Belgian pro-
spective multicenter phase II study in 48 consecutive
patients with CRC and peritoneal carcinomatosis after
CRS and oxaliplatin-based HIPEC. Hompes et al. reported
a median time until recurrence of 19.8 months, and a 2-
year overall survival rate of 88.7% [65]. The differences in
median survival of the control group between these ana-
lyses and the Dutch Trial may be explained by patient se-
lection and the introduction of more efficient combined
chemotherapeutic regimens with or without targeted drugs
in the standard treatment of advanced stage CRC.
Methods/design
Study design
The COMBATAC study is a prospective, multicenter,
open-label, single-arm, single-stage phase II study. The
investigator initiated trial (IIT) is conducted by the De-
partment of Surgery of the University Medical Center
Regensburg in collaboration with the Center for Clinical
Studies Regensburg, the Coordination Centre for Clin-
ical Trials Duesseldorf and the participating national
peritoneal carcinomatosis centers.
The study protocol is supported by the CRC Study
Group of the Arbeitsgemeinschaft Internistische OnkologieOS [mths] Median PFS [mths] OS [%] Survival CC-0/1 [%]
18 - 31 (2-y) -
13 - 32 (2-y) 54 (2-y)
19 - 39 (3-y) 47 (3-y)
16 - 25 (3-y) 44 (3-y)
22 12.6 28 (3-y) 45 (5-y)
37 13 - 58 (3-y)
63 - - 51 (5-y)
- 19.8 - 89 (2y)
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logie (CAO-V) of the German Society of General and
Visceral Surgery (DGAV).
Study objectives and endpoints
The primary objective of the COMBATAC study in
patients with peritoneal carcinomatosis arising from wild-
type KRAS colorectal and appendiceal cancer is to esti-
mate the progression-free survival (PFS). Based on this
estimation, it will be determined whether the multimodal-
ity treatment with pre- and postoperative systemic chemo-
therapy plus cetuximab, cytoreductive surgery (CRS) and
bidirectional hyperthermic intraoperative chemotherapy
(HIPEC) shows sufficient evidence of efficacy for further
investigation.
PFS is defined as the time interval between the first day
of preoperative treatment and the date of progression or
death, whichever occurs first. Patients who are alive and
progression-free at the time of analysis will be censored
for PFS at the time of their last contact.
Secondary endpoints include overall survival, morbidity
and toxicity related to the locoregional approach, feasibi-
lity of the combined treatment concept, quality of life and
pathohistological regression.
Study population
The study population of the COMBATAC study consists
of patients with synchronous or metachronous peritoneal
carcinomatosis arising from histologically proven wild-
type KRAS colorectal or appendiceal cancer. The extent
of peritoneal tumor spread (Peritoneal cancer Index, PCI)
as assessed by diagnostics such as computed tomography
and laparoscopy prior to patient enrolment should allow
complete macroscopic cytoreduction (CC-0/1) at the time
of surgery. Moreover, patients to be included in the study
must meet the following inclusion criteria: treatment-free
interval of at least 6 months after the completion of 3prior
systemic chemotherapy, age over 18 and below 71 years,
good general health status (Karnofsky index more than
70%, ECOG 0–2), absence of hematogenous metastases
(lung, bone, brain, >3 peripheral resectable liver metasta-
ses), absence of contraindication for systemic chemother-
apy and/or extended surgery, estimated life expectancy
more than 6 months, absence of any psychological, famil-
ial, sociological or geographical condition potentially ham-
pering compliance with the study protocol and follow-up
schedule, written informed consent, creatinine clearance
> 50 ml/min, serum creatinine ≤ 1.5 × ULN, serum biliru-
bin ≤ 1.5 × ULN, ASAT and ALAT ≤ 2.5 × ULN, platelet
count > 100,000/ml, haemoglobin > 9 g/dl, neutrophil
granulocytes ≥ 1,500/ml, International Normalized Ration
(INR) ≤ 2, absence of peripheral neuropathy > grade 1
(CTCAE version 4.0), no pregnancy or breast feeding and
adequate contraception in fertile patients. Patients withincomplete cytoreduction (≥CC-2), tumor debulking or
palliative surgery, hematogenous metastasis excluding less
than three resectable liver metastases and/or prior chemo-
therapy < 6 months before evaluation of study inclusion or
therapy with EGFR receptor antibody for metastatic dis-
ease are excluded from the present study. Further exclu-
sion criteria are KRAS mutation, known allergy to murine
or chimeric monoclonal antibodies, concurrent chronic
systemic immune therapy, chemotherapy, or hormone
therapy not indicated in the study protocol, histology of
signet ring carcinoma (>20% of tumor cells), other malig-
nancy than disease under study or second cancer < 5 years
after R0 resection, impaired liver, renal or hematologic
function as mentioned above, heart failure NYHA ≥ 2 or
significant coronary artery disease (CAD), alcohol and/or
drug abuse, inclusion in other clinical trials interfering
with the study protocol. Patients can only be included
once in the COMBATAC study.
Treatment schedule
The interdisciplinary combined treatment regimen con-
sists of pre- and postoperative systemic chemotherapy with
FOLFOX or FOLFIRI plus the EGFR antagonist cetuxi-
mab, cytoreductive surgery (CRS) with complete macro-
scopic cytoreduction (CC-0/1) followed by bidirectional
hyperthermic intraperitoneal chemotherapy (HIPEC). The
treatment schedule is shown in Figure 1.
Systemic chemotherapy will consist of standard-of-care
chemotherapy. Preoperative intravenous chemotherapy
will be applied for 3 months, and therapy will be com-
pleted by postoperative systemic chemotherapy for further
3 months starting 4–6 weeks after surgery. Cetuximab is
given intravenously once weekly for max. 12 weeks. The
initial dose is 400 mg/m2 body surface area followed by a
weekly dose of 250 mg/m2. Standard of care premedica-
tion will be administered as needed to patients receiving
intravenous chemotherapy, including dexamethasone, acid
suppressors, anti-emetics, analgetics and antipyretics. Sys-
temic chemotherapy will be administered by the patients’
medical oncologist or the department of oncology of the
enrolling peritoneal carcinomatosis center. All decisions
regarding the management of (serious) adverse events re-
lated to systemic chemotherapy, such as dose reduction,
interruption of systemic treatment or change of treatment
regimen are at the discretion of the treating medical
oncologist and are allowed within the study protocol, if
documented.
Preoperative systemic chemotherapy is followed by
cytoreductive surgery and HIPEC. The intent of cytore-
ductive surgery is to obtain complete macroscopic cyto-
reduction (CC-0/1) as a precondition for the application
of HIPEC. The residual disease is classified intraope-
ratively using the completeness of cytoreduction (CC)
score. CC-0 indicates no visible residual tumor and CC-1
Preoperative chemotherapy, 3 months
(FOLFOX/FOLFIRI + Cetuximab)
Postoperative chemotherapy, 3 months
(FOLFOX/FOLFIRI + Cetuximab)
Patients with synchronous or metachronous
peritoneal carcinomatosis arising from
colorectal or appendiceal cancer
Inclusion/exclusion criteria
Eligible/written informed consent Not eligible
Incomplete CR
Palliative surgery
Expl. Laparotomy/Laparoscopy
3-monthly Follow-up,
24 months
HIPEC (300 mg/m2 Oxaliplatin ip plus
400 mg/m2 5-FU and 20 mg/m2 FA iv)
CRS (CC-0/1)
Figure 1 Flowchart of the COMBATAC study.
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cate residual tumor nodules between 2.5 mm and 2.5 cm
and > 2.5 cm, respectively [70]. The initial extent of pe-
ritoneal tumor manifestation is determined intraopera-
tively using the Peritoneal Cancer Index (PCI, Washington
Cancer Center), a combined numerical score of lesion size
(LS-0 to LS-3) and tumor localization (region 0–12)
[70,71]. During surgery patients are placed in modified lith-
otomy position. Surgery may include parietal and visceral
peritonectomy, greater omentectomy, splenectomy, chole-
cystectomy, resection of liver capsule, small bowel resec-
tion, colonic and rectal resection, (subtotal) gastrectomy,
lesser omentectomy, pancreatic resection, hysterectomy,
ovariectomy and urine bladder resection. In patients with
infiltration of the umbilicus, omphalectomy is necessary.
Further operating procedures and resections may be neces-
sary due to the intraoperative findings. Gastrointestinal re-
constructions are performed following the individual
center’s standard operating procedures (SOPs). The follow-
ing minimal requirements are prerequisites for CRS:
complete greater omentectomy, complete adhesiolysis of
the small intestine, complete mobilization of the liver to as-
sess the right diaphragmatic space, assessment of the left
diaphragmatic space requiring splenectomy in the majority
of cases, assessment of the left and right paracolic spaces,
assessment of the pelvis, often requiring anterior rectal
resection.
Bidirectional oxaliplatin-based hyperthermic intraperito-
neal chemoperfusion (HIPEC) will only be applied intrao-
peratively in case of complete macroscopic cytoreduction(CC-0/1). HIPEC may be performed in an open or closed
abdomen technique according to the peritoneal carcin-
omatosis center’s SOPs. After CRS four intraabdominal
drains and two temperature probes are placed for continu-
ous abdominal perfusion using a roller pump system with
heat exchanger as described before [72]. When Douglas
pouch temperature reaches 40°C oxaliplatin at a concen-
tration of 300 mg/m2 body surface area is added and per-
fusion will be continued for further 30 minutes. The
treatment is combined with synchronous IV administra-
tion of 400 mg/m2 fluorouracil and 20 mg/m2 folinic acid
considering toxicity and safety instructions. After comple-
tion of the intraperitoneal perfusion cycle, the perfusion
volume is evacuated from the abdominal cavity, all drains
remain in situ and the patient is transferred to postopera-
tive care.
Assessments and follow-up
During the screening period patients will be assessed for
eligibility to be included in the COMBATAC study. Inclu-
sion and exclusion criteria are assessed by the investigator
and initial diagnostics will be completed as necessary prior
to patient enrolment. During pre- and postoperative sys-
temic chemotherapy clinical examination and laboratory
testing will be performed within 7 days of each chemo-
therapy cycle. After completion of preoperative treatment
and after completion of the postoperative chemotherapy
(end of treatment period), a further staging computed tom-
ography will be performed. Moreover, quality of life is
assessed and tumor markers (CEA, CA19-9) are deter-
mined. The same items will be recorded within three weeks
after surgery. Intraoperative data consisting of PCI, surgical
procedures, number of anastomoses, operating time, blood
loss and course of HIPEC procedure and additional post-
operative such as stay on ICU and hospital stay will be
documented. The follow-up time starts 30 days after the
last day of drug administration during postoperative treat-
ment with the ‘end-of-treatment’ visit. The follow-up time
takes 24 months with three-monthly follow-up visits con-
sisting of physical examination, laboratory testing inclu-
ding tumor markers and protocol CT scans. Quality of life
will be assessed yearly during follow-up.
Radiological disease progression will be assessed accord-
ing to the revised RECIST criteria version 1.1 [73]. As
mentioned above, computed tomography of the chest, ab-
domen and pelvis with oral, rectal and intravenous con-
trast will be performed prior to treatment start, within
3 weeks after cytoreductive surgery (CRS) and HIPEC and
30 days after the last systemic drug administration. Res-
ponse to treatment is defined by the following four cat-
egories. (1) complete response (CR), (2) partial response
(PR, 30% decrease in sum of baseline), (3) stable disease
(SD) and (4) progressive disease (PD, new lesions or 20%
increase in sum from nadir). Determination of disease
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disease recurrence will be based on clinical signs or symp-
toms (e.g. malignant ascites, ureteral stenosis or bowel
obstruction), radiological diagnosis (CT ± PET) and/or
surgical evidence of progression during laparoscopy or
laparotomy. In addition, CEA and CA19-9 will be rou-
tinely measured as mentioned above. An at least three fold
increase in serum CEA or CA19-9 levels will be defined as
progression.
Morbidity and toxicity will be assessed as the number
of medical and surgical complications occurring during
the treatment period. The severity of complications
(Grade I-V) will be assessed and adverse events will be
categorized using the CTCAE version 4.0 [74].
Quality of life will be assessed using the EORTC QLQ-
C30 questionnaire. Functional and symptom scores will
be calculated according to the standard scoring proce-
dures [75]. Comparisons will be drawn with the score
means of the reference population [76]. A second round
of analyses will be performed in order to identify the pro-
portion of patients at any assessment point with pro-
nounced deficits in QoL as defined by score points < 50
on a 0 = very bad to 100 = very good scale [77].
The pathohistological regression after systemic chemo-
therapy is assessed and graded using the classification
published by Dworak et al [78]. This classification system
was originally generated to evaluate regression of rectal
cancer after neoadjuvant radiotherapy and consists of dif-
ferent types of necrosis and fibrosis with specific changes
of vascular and cellular morphology.
Statistical considerations
The sample size was calculated using the primary end-
point, i.e. progression-free survival (PFS). Based on the lit-
erature, a median PFS of 10 months or less was considered
to be of no further interest (treatment not promising).
Alpha (one-sided) was set to 10% and Beta was set to 20%
(acceptable error rates for phase II trials [79]). Assuming
exponentially distributed progression times and a target
median PFS of 14 months (treatment promising), at least
39 events (progressions or deaths) have to be observed.
Equivalently, if the true median PFS is 14 months, 39
events will be sufficient to rule out a median PFS of
10 months, based on the one-sided 90% confidence inter-
val (CI). The normal approximation used in the calcula-
tions is given by equation 3.2.7 of Lawless [80]. Assuming
an accrual period of 12 months and a follow-up of at least
18 months from the last patient recruited, a minimum
number of 51 patients will be required. With a lost-to-
follow-up rate of maximal 15%, a total of 60 patients have
to be included in the study.
The final analysis with respect to PFS will be done after
39 observed events. PFS distribution and median PFS time
with the corresponding one-sided 90% CI will be estimatedby means of the Kaplan-Meier method. The treatment will
be considered worth further investigation if the lower
bound of the CI is greater than 10 months. The primary
analysis will be based on the intention-to-treat (ITT) ana-
lysis set that consists of all patients who entered the study.
A detailed description of statistical analysis methods
will be given in the Statistical Analysis Plan which will
be finalized prior to database lock.
Data collection and quality assurance
Patient data are collected in an electronic case report form
(eCRF) at the data centre of the Center for Clinical Studies
Regensburg in collaboration with the Coordination Centre
for Clinical Trials Duesseldorf. Consistency checks will be
performed on newly entered forms and queries issued in
case of inconsistencies. Archiving of trial documents and
trial data is performed according to the internal SOPs of
the Center for Clinical Studies Regensburg. The originals
of all essential trial documents are filed in the Trial Master
File (TMF) and archived for at least 15 years. The site-
specific documents in the Investigator Site File (ISF) will
be archived at the site for at least 15 years. On-site mon-
itoring will be performed by an external CRO (multi-
service-monitoring, Regensburg, Germany) adapted ac-
cording to the site accrual.
Ethical and legal aspects
The protocol will be conducted according to the guide-
lines of Good Clinical Practice (GCP) and the ethical prin-
ciples described in the Declaration of Helsinki. The study
protocol was approved by the leading ethic committee
(Ethikkommission an der Universitaet Regensburg) and
the associated ethics committees, and was also subject
to authorization by the national competent authority
(BfArM) as mandatory by federal law. The study was
assigned the EudraCT number 2009-014040-11 and is
registered at ClinicalTrials.gov (NCT01540344).
Discussion
The COMBATAC study is designed to evaluate the feasi-
bility and efficacy of CRS and bidirectional oxaliplatin-
based HIPEC as an additional treatment option for se-
lected patients within an interdisciplinary combined treat-
ment concept consisting of standard-of care pre- and
postoperative systemic chemotherapy.
It is beyond question that systemic chemotherapy is the
standard of care in patients with advanced stage CRC and
peritoneal carcinomatosis. Although the oncological out-
come of patients with advanced stage CRC and also the
subgroup of patients with peritoneal carcinomatosis has
improved since the introduction of combined chemother-
apeutic regimens and new drugs, results of systemic the-
rapy for patients with peritoneal carcinomatosis are still
unsatisfactory [44]. Thus, additional treatment options
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HIPEC may improve long-term survival of selected pa-
tients with peritoneal carcinomatosis of colonic origin
[59,60]. Moreover, hyperthermic peritoneal perfusion with
oxaliplatin in combination with synchronous intravenous
application of 5-FU/folinic acid seems to improve the effi-
cacy of HIPEC in comparison to a mitomycin C-based
intraperitoneal treatment regimen, and may additionally
contribute to a better local disease control [46,65]. Peri-
operative morbidity and mortality seems not to be im-
paired by the intensified oxaliplatin-based HIPEC regimen
[81]. Nevertheless, the time of surgery including HIPEC,
the perioperative treatment and the sequence of the the-
rapeutic interventions is still a matter of debate. The in-
tensified systemic treatment strategy with preoperative
chemotherapy may lead to increased rates of complete
macrosopic cytoreduction and together with the post-
operative treatment to better control of distant metastasis
and tumor recurrence. However, there is no prospective
study available evaluating the clinical and oncological out-
come after standard-of-care chemotherapy including tar-
geted anticancer therapy in combination with CRS and
HIPEC. Thus, the COMBATAC study is expected to give
further information about the efficacy of this promising
therapeutic option as an inherent part of a multidisciplin-
ary treatment concept.
Conclusions
To our knowledge the COMBATAC study is the first pro-
spective clinical trial investigating the feasibility and efficacy
of CRS and bidirectional oxaliplatin-based HIPEC within
an interdisciplinary treatment regimen with pre- and post-
operative systemic chemotherapy including cetuximab.
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